ReviewCurrent treatment options in neurology2019
Antidepressants for Preventive Treatment of Migraine.
Review in Current treatment options in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 97 citations in OpenAlex.
- Clinical efficacy of escitalopram combined with botulinum toxin A in patients with generalized anxiety disorder and comorbid headache.Psychopharmacology · 2023Trial
- Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.Headache · 2021Trial
- Bioequivalence Study of Amitriptyline Hydrochloride Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions.Drug design, development and therapy · 2020Trial
- Article
- Pharmacologic and Nonpharmacologic Pain Management in Patients with Traumatic Brain Injury: A Multidisciplinary Approach.Journal of clinical medicine · 2025Review
- Do Common Genetic Factors Underlie Comorbidity Between Migraine and Major Depressive Disorder in Youth?Pediatric neurology · 2025Article
- Depressive Symptoms Affect Cognitive Functioning from Middle to Late Adulthood: Ethnoracial Minorities Experience Greater Repercussions.Journal of racial and ethnic health disparities · 2025Article
- Substrate-selective COX-2 inhibition by IMMA attenuates posttraumatic headache via endocannabinoid modulation and neuroinflammatory suppression.The journal of headache and pain · 2025Article
- Mechanistic intersections between migraine and major depressive disorder.The journal of headache and pain · 2025Review
- Prenatal exposure to selective serotonin reuptake inhibitors and risk of disorders of gut-brain interaction in children.Molecular psychiatry · 2025Article
- Impact of Antidepressants on Weight Gain: Underlying Mechanisms and Mitigation Strategies.Archives of clinical and biomedical research · 2025Article
- Causal Relationship Between Migraine and Postpartum Depression: A Two-Sample Bidirectional Mendelian Randomization Study.Journal of pain research · 2025Article
- A Hybrid Digital-4E Strategy for comorbid migraine and depression: a medical hypothesis on an AI-driven, neuroadaptive, and exposome-aware approach.Frontiers in neurology · 2025Article
- Combining treatments for migraine prophylaxis: the state-of-the-art.The journal of headache and pain · 2024Review
- The Antidepressant Drug Amitriptyline Affects Human SH-SY5Y Neuroblastoma Cell Proliferation and Modulates Autophagy.International journal of molecular sciences · 2024Article
- Migraine and Its Treatment from the Medicinal Chemistry Perspective.ACS pharmacology & translational science · 2024Review
- Article
- Antidepressant-like Effects of Representative Types of Food and Their Possible Mechanisms.Molecules (Basel, Switzerland) · 2023Review
- Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review.Neurology and therapy · 2023Review
- Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review describes the pharmacology of each antidepressant class as it applies to migraine prevention, summarizes the evidence base for each medication, and describes relevant side effects and clinical considerations. Use of antidepressants for migraine prevention in clinical practice is also discussed. RECENT
findingsAntidepressants are commonly used as migraine preventives. Amitriptyline has the best evidence for use in migraine prevention. Nortriptyline is an alternative in patients who may not tolerate amitriptyline. The sedating effect of TCAs can be beneficial for patients with comorbid insomnia. SNRIs including venlafaxine and duloxetine also have evidence for efficacy and may be the most effective treatments in patients with comorbid depression and migraine. SSRIs including fluoxetine are not effective for most patients. The side effect burden of antidepressants can be substantial. Patients should be particularly counseled about the possibility of a withdrawal effect from SNRIs. Antidepressants are an important option for preventive treatment of migraine. Further research on the efficacy and tolerability of SNRIs as migraine preventives is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.